Kairos Pharma, Ltd. (KAPA)
NYSEAMERICAN: KAPA · Real-Time Price · USD
0.590
-0.009 (-1.50%)
Apr 28, 2026, 4:00 PM EDT - Market closed
Kairos Pharma Income Statement
Financials in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
| FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
| Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
| Selling, General & Admin | 3.44 | 1.93 | 1.63 | 0.48 | 1.76 | |
| Research & Development | 2.14 | 0.41 | 0.08 | 0.09 | 0.18 | |
| Operating Expenses | 5.57 | 2.34 | 1.71 | 0.57 | 1.94 | |
| Operating Income | -5.57 | -2.34 | -1.71 | -0.57 | -1.94 | |
| Interest Expense | - | -0.19 | -0.1 | -0.46 | -0.16 | |
| Interest & Investment Income | 0.13 | - | - | - | - | |
| Other Non Operating Income (Expenses) | - | -0.67 | - | -0.02 | -0.04 | |
| EBT Excluding Unusual Items | -5.45 | -3.2 | -1.81 | -1.05 | -2.15 | |
| Other Unusual Items | - | 0.6 | - | - | - | |
| Pretax Income | -5.45 | -2.6 | -1.81 | -1.05 | -2.15 | |
| Net Income | -5.45 | -2.6 | -1.81 | -1.05 | -2.15 | |
| Net Income to Common | -5.45 | -2.6 | -1.81 | -1.05 | -2.15 | |
| Shares Outstanding (Basic) | 18 | 11 | 10 | 10 | 9 | |
| Shares Outstanding (Diluted) | 18 | 11 | 10 | 10 | 9 | |
| Shares Change (YoY) | 62.27% | 9.38% | 1.42% | 11.86% | -3.12% | |
| EPS (Basic) | -0.30 | -0.23 | -0.17 | -0.10 | -0.23 | |
| EPS (Diluted) | -0.30 | -0.23 | -0.17 | -0.10 | -0.23 | |
| EBITDA | -5.41 | -2.18 | -1.55 | -0.41 | -1.85 | |
| D&A For EBITDA | 0.16 | 0.16 | 0.16 | 0.16 | 0.1 | |
| EBIT | -5.57 | -2.34 | -1.71 | -0.57 | -1.94 | |
Source: S&P Capital IQ. Standard template.
Financial Sources.